1. American Heart Journal
Rationale and design of POPular-TAVI: antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation 
Vincent Johan Nijenhuis, MD, Naoual Bennaghmouch, MD, Mariella Hassell, MD, Jan Baan, MD, PhD, Jan Peter van Kuijk, MD, PhD, Pierfrancesco Agostoni, MD, PhD, Arnoud van ‘t Hof, MD, PhD, Peter C. Kievit, MD, PhD, Leo Veenstra, MD, Pim van der Harst, MD, PhD, Ad F.M. van den Heuvel, MD, PhD, Peter den Heijer, MD, PhD, Johannes C. Kelder, MD, PhD, Vera H. Deneer, PharmD, PhD, Frank van der Kley, MD, Francesco Onorati, MD, PhD, Jean Philippe Collet, MD, PhD, Francesco Maisano, MD, PhD, Azeem Latib, MD, PhD, Kurt Huber, MD, PhD, Pieter R. Stella, MD, PhD, Jurrien M. ten Berg, MD, PhD 
American Heart Journal 
Volume 173, Pages (March 2016)
DOI: /j.ahj
Copyright © 2015 Elsevier Inc. Terms and Conditions

2. Figure
POPular TAVI study design. After inclusion, patients are stratified according to the presence or absence of OAC therapy. The day before TAVI, patients are randomized in a 1:1 manner to clopidogrel or no clopidogrel in addition to aspirin (cohort A) or OAC (cohort B).
American Heart Journal  , 77-85DOI: ( /j.ahj )
Copyright © 2015 Elsevier Inc. Terms and Conditions